Kronos Bio

Pursuing therapies against some of the most intractable cancer targets.

Kronos Bio is dedicated to the research and development of first-in class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research. 

This company is a spin-out from the 2015 project, Exploring the Therapeutic Potential of Small Molecules that Modulate the c-Myc Oncoprotein